Related Experiment Video
Updated: Sep 20, 2025
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Feasibility and Efficacy of Cell-Free Ascites Reinfusion Therapy for Pseudomyxoma Peritonei: A Single-Center,
Takahiro Kaneko1, Yuki Otake1,2, Daisuke Katagiri3
1Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Introduction:
Limited treatments are available for the highly mucinous Pseudomyxoma Peritonei (PMP)-related ascites. This study assessed the feasibility and efficacy of cell-free ascites reinfusion therapy (CART) for PMP-related ascites.
Methods:
Patients with PMP who underwent CART between 2017 and 2021 were included. We retrospectively collected clinical data and compared pre- and post-CART clinical features and symptoms.
Results:
Nine patients with PMP underwent 12 CART sessions. A wild-bore chest tube was used in 25% (3/12) of sessions, with no severe complications. Abdominal pain and food intake improved in 92% (11/12) and 42% (5/12) of sessions, respectively (median decrease in weight, -4.4 kg [p = 0.02]). Serum albumin and creatinine levels did not change significantly (p = 0.280 vs. p > 0.500). Mild fever occurred during or after CART in 67% (9/12) of sessions; severe complications were not observed.
Conclusion:
CART may be a relatively safe and affordable treatment for PMP-related ascites.
Insights
Cell-free ascites reinfusion therapy (CART) offers a safe and affordable option for managing Pseudomyxoma Peritonei (PMP)-related ascites. This treatment improved symptoms like abdominal pain and weight in patients with PMP.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Innovation
Background:
- Pseudomyxoma Peritonei (PMP) presents limited treatment options for ascites.
- Ascites in PMP significantly impacts patient quality of life.
Purpose of the Study:
- To evaluate the feasibility and efficacy of cell-free ascites reinfusion therapy (CART) for PMP-related ascites.
- To assess the safety and impact of CART on patient symptoms and clinical parameters.
Main Methods:
- Retrospective analysis of nine patients with PMP undergoing CART between 2017 and 2021.
- Comparison of clinical features and symptoms before and after CART sessions.
Main Results:
- CART was performed in 12 sessions with no severe complications observed.
- Significant improvement in abdominal pain (92%) and weight (median -4.4kg) was noted.
- Mild fever occurred in 67% of sessions, but was not a severe complication.
Conclusions:
- Cell-free ascites reinfusion therapy (CART) demonstrates potential as a safe and affordable treatment for PMP ascites.
- CART may offer symptomatic relief and improve quality of life for PMP patients.
